JPX : 4588.T

Oncolys BioPharma Inc.

$2741 JPY

$71 (2.66%)

Volume
534.1K
Average Volume
1.26M
Market Capitalization
$68.22B
P/E Ratio
-43.32
Dividend Yield
0.00%
Price Target
Year High
$3695.00
Year Low
$571.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$5.12
Company Overview

JPX

Yasuo Urata

Biotechnology

Healthcare

4588.T

44

JP

JPY

https://www.oncolys.com

81 3 5472 1578

N/A

N/A

Liquidity Metrics

0.20

5.12

5.11

4.04

0.00

Sales & Valuation

$28.55M

2156.30

22.33

-35.09

-66.40

Profitability

-$80

-$2.06B

-5249.96%

-5236.41%

-61.50%

-36.68%

P/E Metrics

-43.32

-1.22

-1.22

Analyst Price Target & Rating

Sell

2/5

0 Analysts

%

Financial Health Scores

42.71

2/9

$3.6B

$4.53B

$935.18M

-$1.66B

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Magnus Jaderberg Chief Medical Officer of Oncolys USA Inc.
Yasunari Kashihara MD of Business Development & Risk Management and Director
Yasuo Urata Chairman, Chief Executive Officer & President
Talia Biran President Oncolys USA Inc.
Tetsuji Yoneo Accounting & Finance Manager
Poll Results

No votes yet today — be the first to share your view!

About Oncolys BioPharma Inc. (JPX:4588.T) Stock

Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase ... IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.

Frequently Asked Questions

What is the current Oncolys BioPharma Inc. (4588.T) stock price?

Oncolys BioPharma Inc.(JPX:4588.T) stock price is $2741 in the last trading session. During the trading session, 4588.T stock reached the peak price of $3695 while $571 was the lowest point it dropped to. The percentage change in 4588.T stock occurred in the recent session was 2.66% while the dollar amount for the price change in 4588.T stock was $71.

4588.T's industry and sector of operation?

The JPX listed 4588.T is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of 4588.T?

Magnus Jaderberg | Chief Medical Officer of Oncolys USA Inc.
Yasunari Kashihara | MD of Business Development & Risk Management and Director
Yasuo Urata | Chairman, Chief Executive Officer & President
Talia Biran | President Oncolys USA Inc.
Tetsuji Yoneo | Accounting & Finance Manager

How many employees does 4588.T have?

Number of 4588.T employees currently stands at 44. 4588.T operates from Toranomon Towers Office, Tokyo, TY 105-0001, JP.

Link for 4588.T official website?

Official Website of 4588.T is: https://www.oncolys.com

How do I contact 4588.T?

4588.T could be contacted at phone #81 3 5472 1578 and can also be accessed through its website. 4588.T operates from Toranomon Towers Office, Tokyo, TY 105-0001, JP.

How many shares of 4588.T are traded daily?

The average number of 4588.T shares traded daily for last 3 months was 1.26M.

What is the market cap of 4588.T currently?

The market value of 4588.T currently stands at $68.22B with its latest stock price at $2741